 Steven Thorpe
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 20 | 2024 | 192 | 5.320 |
Why?
| | Soft Tissue Neoplasms | 11 | 2024 | 116 | 3.810 |
Why?
| | Bone Neoplasms | 14 | 2025 | 250 | 2.610 |
Why?
| | Margins of Excision | 3 | 2024 | 50 | 1.840 |
Why?
| | Intraoperative Care | 2 | 2024 | 49 | 1.130 |
Why?
| | Osteosarcoma | 5 | 2025 | 75 | 0.970 |
Why?
| | Frozen Sections | 1 | 2024 | 26 | 0.910 |
Why?
| | Surgical Oncology | 1 | 2024 | 27 | 0.890 |
Why?
| | Extremities | 7 | 2023 | 130 | 0.550 |
Why?
| | Sarcoma, Ewing | 3 | 2025 | 95 | 0.550 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1312 | 0.490 |
Why?
| | Tomography, X-Ray Computed | 3 | 2024 | 2681 | 0.460 |
Why?
| | Subtalar Joint | 1 | 2012 | 4 | 0.390 |
Why?
| | Flatfoot | 1 | 2012 | 12 | 0.380 |
Why?
| | Sarcoma, Synovial | 2 | 2023 | 21 | 0.380 |
Why?
| | Medical Oncology | 2 | 2025 | 290 | 0.370 |
Why?
| | Subclavian Artery | 1 | 2011 | 28 | 0.350 |
Why?
| | Deltoid Muscle | 1 | 2010 | 6 | 0.350 |
Why?
| | Cellulitis | 1 | 2011 | 54 | 0.350 |
Why?
| | Thoracic Vertebrae | 1 | 2011 | 78 | 0.340 |
Why?
| | Compartment Syndromes | 1 | 2010 | 25 | 0.340 |
Why?
| | Prognosis | 13 | 2024 | 4030 | 0.330 |
Why?
| | Joint Instability | 1 | 2012 | 170 | 0.320 |
Why?
| | Deglutition Disorders | 1 | 2011 | 143 | 0.310 |
Why?
| | Osteomyelitis | 1 | 2011 | 137 | 0.300 |
Why?
| | Humans | 45 | 2025 | 137509 | 0.290 |
Why?
| | Health Status Disparities | 2 | 2021 | 285 | 0.290 |
Why?
| | SEER Program | 4 | 2021 | 218 | 0.290 |
Why?
| | Retrospective Studies | 14 | 2024 | 15628 | 0.270 |
Why?
| | Neoplasms | 4 | 2022 | 2664 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 1060 | 0.240 |
Why?
| | Social Class | 3 | 2023 | 277 | 0.240 |
Why?
| | Socioeconomic Factors | 4 | 2023 | 1286 | 0.240 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5138 | 0.230 |
Why?
| | Knee | 1 | 2025 | 67 | 0.230 |
Why?
| | Middle Aged | 18 | 2025 | 33353 | 0.230 |
Why?
| | Synovitis, Pigmented Villonodular | 1 | 2024 | 3 | 0.220 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 1 | 2024 | 4 | 0.220 |
Why?
| | Survival Rate | 7 | 2024 | 1979 | 0.220 |
Why?
| | Young Adult | 10 | 2025 | 13241 | 0.220 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 591 | 0.220 |
Why?
| | Killer Cells, Natural | 3 | 2023 | 446 | 0.220 |
Why?
| | Subcutaneous Fat | 1 | 2024 | 80 | 0.210 |
Why?
| | Thorax | 1 | 2023 | 47 | 0.210 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 91 | 0.210 |
Why?
| | Muscle, Skeletal | 2 | 2025 | 1701 | 0.200 |
Why?
| | Femoral Neoplasms | 1 | 2022 | 9 | 0.200 |
Why?
| | Musculoskeletal Diseases | 1 | 2023 | 77 | 0.190 |
Why?
| | Neoplasm Staging | 2 | 2023 | 1377 | 0.190 |
Why?
| | Bone Diseases | 1 | 2022 | 63 | 0.190 |
Why?
| | Foot Diseases | 1 | 2021 | 16 | 0.180 |
Why?
| | Adult | 15 | 2025 | 37818 | 0.180 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7591 | 0.180 |
Why?
| | Arthrodesis | 2 | 2012 | 31 | 0.180 |
Why?
| | Knee Joint | 1 | 2025 | 405 | 0.180 |
Why?
| | Osteoarthritis | 1 | 2024 | 185 | 0.180 |
Why?
| | Neoadjuvant Therapy | 3 | 2021 | 405 | 0.180 |
Why?
| | Radiotherapy, Adjuvant | 4 | 2023 | 218 | 0.170 |
Why?
| | Walking | 1 | 2025 | 516 | 0.170 |
Why?
| | Radiation Oncology | 1 | 2021 | 83 | 0.170 |
Why?
| | Male | 20 | 2025 | 67715 | 0.170 |
Why?
| | Reoperation | 2 | 2022 | 569 | 0.170 |
Why?
| | Societies, Medical | 1 | 2024 | 820 | 0.170 |
Why?
| | Interleukin-15 | 1 | 2020 | 97 | 0.170 |
Why?
| | Body Composition | 1 | 2024 | 668 | 0.170 |
Why?
| | Insurance, Health | 1 | 2022 | 282 | 0.160 |
Why?
| | Hand | 1 | 2021 | 160 | 0.160 |
Why?
| | Female | 20 | 2025 | 73160 | 0.160 |
Why?
| | Aged | 11 | 2024 | 23795 | 0.160 |
Why?
| | Arteries | 1 | 2021 | 269 | 0.160 |
Why?
| | Spine | 1 | 2021 | 174 | 0.160 |
Why?
| | Health Equity | 1 | 2021 | 99 | 0.160 |
Why?
| | Combined Modality Therapy | 2 | 2025 | 1241 | 0.160 |
Why?
| | Thoracic Wall | 1 | 2019 | 18 | 0.160 |
Why?
| | Hematologic Neoplasms | 1 | 2021 | 156 | 0.160 |
Why?
| | Thoracic Neoplasms | 1 | 2019 | 37 | 0.150 |
Why?
| | Radiography | 2 | 2012 | 834 | 0.150 |
Why?
| | Healthcare Disparities | 2 | 2023 | 651 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 210 | 0.150 |
Why?
| | Vascular Surgical Procedures | 1 | 2021 | 300 | 0.150 |
Why?
| | Hemipelvectomy | 1 | 2018 | 2 | 0.150 |
Why?
| | Chondrosarcoma | 1 | 2018 | 17 | 0.140 |
Why?
| | Lower Extremity | 1 | 2022 | 427 | 0.140 |
Why?
| | Postoperative Complications | 3 | 2019 | 2641 | 0.140 |
Why?
| | Adolescent | 10 | 2024 | 21552 | 0.130 |
Why?
| | Radiotherapy | 1 | 2018 | 201 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 917 | 0.130 |
Why?
| | Free Tissue Flaps | 1 | 2018 | 64 | 0.130 |
Why?
| | Osteotomy | 2 | 2022 | 120 | 0.130 |
Why?
| | Preoperative Care | 1 | 2019 | 356 | 0.130 |
Why?
| | Child | 10 | 2024 | 22034 | 0.130 |
Why?
| | Transcription Factors | 1 | 2024 | 1718 | 0.130 |
Why?
| | Databases, Factual | 2 | 2021 | 1351 | 0.120 |
Why?
| | Health Care Costs | 1 | 2019 | 387 | 0.120 |
Why?
| | Lymphocytes | 1 | 2018 | 395 | 0.120 |
Why?
| | Body Mass Index | 1 | 2024 | 2369 | 0.120 |
Why?
| | C-Reactive Protein | 1 | 2018 | 411 | 0.120 |
Why?
| | Incidence | 4 | 2021 | 2791 | 0.110 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 682 | 0.110 |
Why?
| | Age Factors | 3 | 2021 | 3299 | 0.110 |
Why?
| | United States | 8 | 2022 | 14695 | 0.100 |
Why?
| | Infant, Newborn | 5 | 2024 | 6058 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1800 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2022 | 10821 | 0.100 |
Why?
| | Tarsal Bones | 1 | 2012 | 13 | 0.100 |
Why?
| | Neutrophils | 1 | 2018 | 1238 | 0.090 |
Why?
| | Torso | 2 | 2023 | 33 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5772 | 0.090 |
Why?
| | California | 2 | 2024 | 425 | 0.090 |
Why?
| | Infant | 5 | 2024 | 9464 | 0.090 |
Why?
| | Debridement | 1 | 2011 | 84 | 0.090 |
Why?
| | Immobilization | 1 | 2010 | 44 | 0.090 |
Why?
| | Osseointegration | 1 | 2011 | 71 | 0.080 |
Why?
| | Child, Preschool | 5 | 2024 | 11094 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2011 | 305 | 0.080 |
Why?
| | Cervical Vertebrae | 1 | 2011 | 135 | 0.080 |
Why?
| | Necrosis | 1 | 2010 | 244 | 0.080 |
Why?
| | Pain Measurement | 1 | 2012 | 552 | 0.080 |
Why?
| | Orthopedic Procedures | 1 | 2012 | 222 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1263 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 7598 | 0.080 |
Why?
| | Recovery of Function | 1 | 2012 | 662 | 0.070 |
Why?
| | Spinal Fusion | 1 | 2011 | 251 | 0.070 |
Why?
| | Risk Assessment | 2 | 2018 | 3439 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 683 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2012 | 617 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 5728 | 0.060 |
Why?
| | Sex Factors | 2 | 2021 | 2072 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2020 | 690 | 0.060 |
Why?
| | Pain | 1 | 2011 | 836 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3722 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2838 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2024 | 80 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 270 | 0.050 |
Why?
| | Smoking | 1 | 2011 | 1639 | 0.050 |
Why?
| | Electromyography | 1 | 2025 | 400 | 0.050 |
Why?
| | Range of Motion, Articular | 1 | 2025 | 392 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2023 | 184 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1695 | 0.050 |
Why?
| | Biomechanical Phenomena | 1 | 2025 | 768 | 0.050 |
Why?
| | Antibiotic Prophylaxis | 1 | 2023 | 117 | 0.050 |
Why?
| | Bone Marrow | 1 | 2023 | 286 | 0.050 |
Why?
| | Prosthesis Failure | 1 | 2022 | 116 | 0.050 |
Why?
| | Vascular Grafting | 1 | 2021 | 13 | 0.050 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2024 | 429 | 0.050 |
Why?
| | Genetic Testing | 1 | 2024 | 453 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 868 | 0.050 |
Why?
| | Sacrum | 1 | 2022 | 80 | 0.050 |
Why?
| | Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2021 | 3 | 0.050 |
Why?
| | Vascular Patency | 1 | 2021 | 105 | 0.050 |
Why?
| | Prosthesis Implantation | 1 | 2022 | 153 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 228 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 309 | 0.040 |
Why?
| | Bone and Bones | 1 | 2023 | 317 | 0.040 |
Why?
| | Femur | 1 | 2022 | 263 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2023 | 306 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2024 | 549 | 0.040 |
Why?
| | Dogs | 1 | 2020 | 411 | 0.040 |
Why?
| | Sarcopenia | 1 | 2020 | 82 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 420 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1402 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 892 | 0.040 |
Why?
| | Organ Preservation | 1 | 2018 | 102 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2018 | 331 | 0.030 |
Why?
| | Perfusion | 1 | 2018 | 211 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 3420 | 0.030 |
Why?
| | Mice | 2 | 2024 | 17843 | 0.030 |
Why?
| | Biocompatible Materials | 1 | 2020 | 424 | 0.030 |
Why?
| | Tissue Engineering | 1 | 2020 | 418 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 502 | 0.030 |
Why?
| | Animals | 3 | 2024 | 37009 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1580 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1320 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1132 | 0.030 |
Why?
| | Wound Healing | 1 | 2018 | 327 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 540 | 0.030 |
Why?
| | Ischemia | 1 | 2018 | 408 | 0.030 |
Why?
| | Registries | 1 | 2021 | 2021 | 0.030 |
Why?
| | Medicare | 1 | 2019 | 747 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2039 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 144 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2012 | 267 | 0.020 |
Why?
| | Pseudarthrosis | 1 | 2011 | 12 | 0.020 |
Why?
| | Spinal Stenosis | 1 | 2011 | 29 | 0.020 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2012 | 143 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2197 | 0.020 |
Why?
| | Radiculopathy | 1 | 2011 | 35 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 231 | 0.020 |
Why?
| | Chemoradiotherapy | 1 | 2012 | 226 | 0.020 |
Why?
| | Bone Transplantation | 1 | 2011 | 95 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2869 | 0.020 |
Why?
| | Risk Factors | 1 | 2022 | 10355 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6817 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1465 | 0.020 |
Why?
|
|
Thorpe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|